NCT04609930已完成不适用
Impact of Immune Checkpoint Inhibitor Therapy on Type 2 Inflammation
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 143
- 试验地点
- 1
- 主要终点
- Change in % eosinophilia after initiation of anti-PD-1 and/or anti-PD-L1
研究概览
简要总结
The primary objective of this study is to determine the impact of anti-checkpoint immunotherapy on type 2 inflammation via a retrospective analysis of % eosinophilia.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Electronic patient file "DxCare" at the University Hospitals of Montpellier
- •Patient has received anti-PD-1 immunotherapy --AND/OR -- anti-PD-L1 immunotherapy according to central pharmacy records
排除标准
- •No mention of % eosinophilia in the patient file
研究组 & 干预措施
The study population
Patients in the University Hospitals of Montpellier system who have received anti-PD-1 and/or anti-PD-L1
干预措施: Anti-PD-1 or anti-PD-L1 (Drug)
结局指标
主要结局
Change in % eosinophilia after initiation of anti-PD-1 and/or anti-PD-L1
时间窗: Before treatment (before day 0) versus after (12 months)
次要结局
- Indication leading to anti-PD-1 and/or anti-PD-L1 immunotherapies(Day 0)
- Age (years)(Day 0)
- Sex (male/female)(Day 0)
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
Immunotherapy Study for Patients With Stage IV MelanomaStage IV MelanomaMetastatic MelanomaNCT02054520NewLink Genetics Corporation47
终止
2 期
Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial CarcinomaUrothelial CarcinomaNCT04322643Case Comprehensive Cancer Center4
尚未招募
不适用
Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeted Drugs / Locoregional Therapy in the Treatment of Hepatocellular CarcinomaImmune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeting Drugs / Locoregional Therapy for Hepatocellular CarcinomaNCT05609695Sun Yat-sen University100
进行中（未招募）
2 期
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial CarcinomaLocally Advanced Bladder Urothelial CarcinomaLocally Advanced Renal Pelvis Urothelial CarcinomaLocally Advanced Ureter Urothelial CarcinomaLocally Advanced Urethral Urothelial CarcinomaLocally Advanced Urothelial CarcinomaMetastatic Bladder Urothelial CarcinomaMetastatic Renal Pelvis Urothelial CarcinomaMetastatic Ureter Urothelial CarcinomaMetastatic Urethral Urothelial CarcinomaMetastatic Urothelial CarcinomaStage IV Bladder Cancer AJCC v8Stage IV Renal Pelvis Cancer AJCC v8Stage IV Ureter Cancer AJCC v8Stage IV Urethral Cancer AJCC v8NCT04848519Emory University6
撤回
4 期
Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for HypophosphatasiaHypophosphatasiaNCT06015750Alexion Pharmaceuticals, Inc.8